Media coverage
17Media coverage
Title U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Media name/outlet CNBC Country United States Date 2/5/16 Persons Fred Poordad Title U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Media name/outlet Bloomberg Country United States Date 2/5/16 Persons Fred Poordad Title U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Media name/outlet Reuters Country United Kingdom Date 2/5/16 Persons Fred Poordad Title U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Media name/outlet Business Wire Country United States Date 2/5/16 Persons Fred Poordad Title U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Media name/outlet Wall Street Select Country United States Date 2/5/16 Persons Fred Poordad Title U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Media name/outlet Yahoo! Finance Country United States Date 2/5/16 Persons Fred Poordad Title U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Media name/outlet MoneyShow.com Country United States Date 2/5/16 Persons Fred Poordad Title U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Media name/outlet Pettinga Financial Advisors Country United States Date 2/5/16 Persons Fred Poordad Title U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Media name/outlet EON: Enhanced Online News Country United States Date 2/5/16 Persons Fred Poordad Title U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Media name/outlet BioSpace Country United States Date 2/5/16 Persons Fred Poordad Title U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Media name/outlet Yahoo! Finance UK and Ireland Date 2/5/16 Persons Fred Poordad Title U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Media name/outlet Yahoo! Singapore Country Singapore Date 2/5/16 Persons Fred Poordad Title U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Media name/outlet Freshnews.com Country United States Date 2/5/16 Persons Fred Poordad Title U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Media name/outlet PipelineReview Country Spain Date 2/5/16 Persons Fred Poordad Title U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Media name/outlet Stock Nod Country United States Date 2/5/16 Persons Fred Poordad Title U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Media name/outlet Bristol-Myers Squibb Country United States Date 2/5/16 Persons Fred Poordad Title U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Media name/outlet BioPortfolio Country United Kingdom Date 2/5/16 Persons Fred Poordad